Biosolution Co., Ltd. (086820) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biosolution Co., Ltd. (086820:KRX), powered by AI.

Current Price
₩6,970
P/E Ratio
661.0
Market Cap
180.7B
Sector
Healthcare
What is the Biosolution Co., Ltd. stock price forecast?

Biosolution Co., Ltd. is currently trading at ₩6,970. View real-time AI analysis on Alpha Lenz.

What is Biosolution Co., Ltd. insider trading activity?

View the latest insider trading data for Biosolution Co., Ltd. on Alpha Lenz.

What is Biosolution Co., Ltd.'s P/E ratio?

Biosolution Co., Ltd.'s P/E ratio is 661.0.

Biosolution Co., Ltd.

KRX · 086820
₩6,970+90(+1.31%)Market closedKRX regular session 09:00–15:30 KST
Ask about Biosolution Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Biosolution Co., Ltd. trades at a P/E of 661.0 (premium valuation) with modest ROE of 0.9%. 3Y revenue CAGR of 14.6% highlights clear growth momentum.

Ask for details

Company Overview

Biosolution Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and commercialization of advanced bioengineering products and technologies. This company is primarily engaged in the creation of bio-based solutions for medical applications, including cell therapy and regenerative medicine, which are crucial for advancing modern healthcare treatments. Biosolution Co., Ltd. focuses on leveraging its expertise in stem cell research and technology to deliver innovative therapeutic products aimed at treating a variety of diseases and injuries. By emphasizing cutting-edge research and development, the company significantly contributes to enhancing treatment outcomes and expanding the potential of regenerative science. In the financial market, Biosolution Co., Ltd. plays a vital role as a technology-driven innovator within the healthcare industry, attracting attention for its potential to address unmet medical needs and for its contributions to scientific advancement. This underscores its significance in both healthcare and biotechnology sectors, where ongoing research can lead to breakthrough therapies and improved patient care.

CEO이정선
SectorHealthcare
IndustryBiotechnology
Employees71

Company Statistics

FY 2025

Profile

₩180,690,872,450Market Cap
₩15,199,886,700Revenue
25.92MShares Out
71Employees

Margins

63.09%Gross
20.17%EBITDA
-28.56%Operating
1.80%Pre-Tax
1.80%Net

Valuation

661.00P/E
5.65P/B
11.89EV/Sales
64.86EV/EBITDA
-88.44P/FCF

Growth (CAGR)

14.59%Rev 3Yr
14.44%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

0.40%ROA
0.86%ROE
4.54%ROIC

Financial Health

₩11,882,795,470Cash & Cash Equivalents
₩24,594,456,600Net Debt
113.98%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Biosolution Co., Ltd. (ticker: 086820) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 71 employees. Market cap is $180.7B.

The current price is ₩6,970 with a P/E ratio of 661x and P/B of 5.65x.

ROE is 0.86% and operating margin is -28.56%. Annual revenue is $15.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Biosolution Co., Ltd. (086820) Stock Forecast 2026 ₩6,970 — Price, Financials & Analyst Targets | Alpha Lenz